Jazz Pharmaceuticals (JAZZ) Stock Forecast & Price Target

Compare

1,860 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

JAZZ Analyst Ratings

Strong Buy

12 Buy

1 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Jazz

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

JAZZ Stock 12 Month Forecast

Average Price Target

$219.54

▲(28.27% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Jazz Pharmaceuticals in the last 3 months. The average price target is $219.54 with a high forecast of $263.00 and a low forecast of $188.00. The average price target represents a 28.27% change from the last price of $171.16.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"107":"$107","264":"$264","146.25":"$146.3","185.5":"$185.5","224.75":"$224.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":263,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$263.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":219.54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$219.54</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":188,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$188.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[107,146.25,185.5,224.75,264],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,170,177.15384615384616,184.30769230769232,191.46153846153845,198.6153846153846,205.76923076923077,212.92307692307693,220.0769230769231,227.23076923076923,234.3846153846154,241.53846153846155,248.69230769230768,255.84615384615387,{"y":263,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,170,173.81076923076924,177.62153846153845,181.4323076923077,185.24307692307693,189.05384615384617,192.86461538461538,196.67538461538462,200.48615384615385,204.29692307692306,208.1076923076923,211.91846153846154,215.72923076923075,{"y":219.54,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,170,171.3846153846154,172.76923076923077,174.15384615384616,175.53846153846155,176.92307692307693,178.30769230769232,179.69230769230768,181.07692307692307,182.46153846153845,183.84615384615384,185.23076923076923,186.6153846153846,{"y":188,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":123.15,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.37,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.99,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.18,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.44,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":115.52,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":129.66,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":136.9,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.64,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172.12,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":170,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$263.00

Average Price Target$219.54

Lowest Price Target$188.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jason Gerberry

Bank of America Securities

$263

Buy

53.66%

Upside

Reiterated

01/16/26

Analysts Offer Insights on Healthcare Companies: Privia Health Group (NASDAQ: PRVA), Jazz Pharmaceuticals (NASDAQ: JAZZ) and Annexon Biosciences (NASDAQ: ANNX)

Mohit Bansal

Wells Fargo

$235

Buy

37.30%

Upside

Reiterated

01/16/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ) and AbbVie (NYSE: ABBV)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$225

Buy

31.46%

Upside

Reiterated

01/13/26

Jazz Pharmaceuticals (JAZZ) Gets a Buy from Jefferies

Joon Lee

Truist Financial

$220→$230

Buy

34.38%

Upside

Reiterated

01/12/26

Raising our PT from $220 to $230.

Ami Fadia

Needham

$235

Buy

37.30%

Upside

Reiterated

01/12/26

Buy Rating on Jazz Pharmaceuticals Driven by Zanidatamab’s Differentiated Efficacy and Clear Regulatory Path in First-Line HER2+ GEA

Leonid Timashev

RBC Capital

$194→$191

Buy

11.59%

Upside

Reiterated

01/09/26

Sean Laaman

Morgan Stanley

$205→$225

Buy

31.46%

Upside

Reiterated

01/08/26

Jazz Pharmaceuticals price target raised to $225 from $205 at Morgan StanleyJazz Pharmaceuticals price target raised to $225 from $205 at Morgan Stanley

Annabel Samimy

Stifel Nicolaus

$230

Buy

34.38%

Upside

Reiterated

01/07/26

Jazz Pharmaceuticals (JAZZ) Gets a Buy from Stifel Nicolaus

David Amsellem

Piper Sandler

$147→$219

Buy

27.95%

Upside

Reiterated

12/10/25

Jazz Pharmaceuticals price target raised to $219 from $147 at Piper SandlerJazz Pharmaceuticals price target raised to $219 from $147 at Piper Sandler

Ashwani Verma

UBS

$188

Hold

9.84%

Upside

Downgraded

11/24/25

Hold Rating for Jazz Pharmaceuticals Amid Balanced Risk-Reward and Competitive Challenges

Brian Skorney

Robert W. Baird

$160→$209

Buy

22.11%

Upside

Reiterated

11/18/25

Jazz Pharmaceuticals price target raised to $209 from $160 at BairdJazz Pharmaceuticals price target raised to $209 from $160 at Baird

Joseph Thome

TD Cowen

$205

Buy

19.77%

Upside

Reiterated

11/06/25

Jazz Pharmaceuticals: Strong Financial Performance and Promising Prospects Reinforce Buy Rating

Jessica Fye

J.P. Morgan

$204→$199

Buy

16.27%

Upside

Reiterated

10/27/25

Jazz Pharmaceuticals price target lowered to $199 from $204 at JPMorganJazz Pharmaceuticals price target lowered to $199 from $204 at JPMorgan

Marc Goodman

Leerink Partners

$220→$215

Buy

25.61%

Upside

Reiterated

10/07/25

Jazz Pharmaceuticals (JAZZ) Receives a Buy from Leerink Partners

David Hoang

Deutsche Bank

$170→$173

Buy

1.08%

Upside

Reiterated

10/03/25

Deutsche Bank Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jason Gerberry

Bank of America Securities

$263

Buy

53.66%

Upside

Reiterated

01/16/26

Analysts Offer Insights on Healthcare Companies: Privia Health Group (NASDAQ: PRVA), Jazz Pharmaceuticals (NASDAQ: JAZZ) and Annexon Biosciences (NASDAQ: ANNX)

Mohit Bansal

Wells Fargo

$235

Buy

37.30%

Upside

Reiterated

01/16/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ) and AbbVie (NYSE: ABBV)

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$225

Buy

31.46%

Upside

Reiterated

01/13/26

Jazz Pharmaceuticals (JAZZ) Gets a Buy from Jefferies

Joon Lee

Truist Financial

$220→$230

Buy

34.38%

Upside

Reiterated

01/12/26

Raising our PT from $220 to $230.

Ami Fadia

Needham

$235

Buy

37.30%

Upside

Reiterated

01/12/26

Buy Rating on Jazz Pharmaceuticals Driven by Zanidatamab’s Differentiated Efficacy and Clear Regulatory Path in First-Line HER2+ GEA

Leonid Timashev

RBC Capital

$194→$191

Buy

11.59%

Upside

Reiterated

01/09/26

Sean Laaman

Morgan Stanley

$205→$225

Buy

31.46%

Upside

Reiterated

01/08/26

Jazz Pharmaceuticals price target raised to $225 from $205 at Morgan StanleyJazz Pharmaceuticals price target raised to $225 from $205 at Morgan Stanley

Annabel Samimy

Stifel Nicolaus

$230

Buy

34.38%

Upside

Reiterated

01/07/26

Jazz Pharmaceuticals (JAZZ) Gets a Buy from Stifel Nicolaus

David Amsellem

Piper Sandler

$147→$219

Buy

27.95%

Upside

Reiterated

12/10/25

Jazz Pharmaceuticals price target raised to $219 from $147 at Piper SandlerJazz Pharmaceuticals price target raised to $219 from $147 at Piper Sandler

Ashwani Verma

UBS

$188

Hold

9.84%

Upside

Downgraded

11/24/25

Hold Rating for Jazz Pharmaceuticals Amid Balanced Risk-Reward and Competitive Challenges

Brian Skorney

Robert W. Baird

$160→$209

Buy

22.11%

Upside

Reiterated

11/18/25

Jazz Pharmaceuticals price target raised to $209 from $160 at BairdJazz Pharmaceuticals price target raised to $209 from $160 at Baird

Joseph Thome

TD Cowen

$205

Buy

19.77%

Upside

Reiterated

11/06/25

Jazz Pharmaceuticals: Strong Financial Performance and Promising Prospects Reinforce Buy Rating

Jessica Fye

J.P. Morgan

$204→$199

Buy

16.27%

Upside

Reiterated

10/27/25

Jazz Pharmaceuticals price target lowered to $199 from $204 at JPMorganJazz Pharmaceuticals price target lowered to $199 from $204 at JPMorgan

Marc Goodman

Leerink Partners

$220→$215

Buy

25.61%

Upside

Reiterated

10/07/25

Jazz Pharmaceuticals (JAZZ) Receives a Buy from Leerink Partners

David Hoang

Deutsche Bank

$170→$173

Buy

1.08%

Upside

Reiterated

10/03/25

Deutsche Bank Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Jazz Pharmaceuticals

3 Months

xxx

Success Rate

22/34 ratings generated profit

Average Return

+2.34%

reiterated a xxx

rating yesterday

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.71% of your transactions generating a profit, with an average return of +2.34% per trade.

1 Year

Joon LeeTruist Financial

Success Rate

16/20 ratings generated profit

Average Return

+16.25%

reiterated a buy rating 5 days ago

Copying Joon Lee's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +16.25% per trade.

2 Years

xxx

Success Rate

17/20 ratings generated profit

Average Return

+27.02%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 85.00% of your transactions generating a profit, with an average return of +27.02% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

JAZZ Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, JAZZ has received 30 Buy Ratings, 21 Hold Ratings, and 0 Sell Ratings. JAZZ average Analyst price target in the past 3 months is 219.54.

Each month's total comprises the sum of three months' worth of ratings.

JAZZ Financial Forecast

JAZZ Earnings Forecast

Next quarter’s earnings estimate for JAZZ is $6.39 with a range of $5.81 to $6.77. The previous quarter’s EPS was $8.13. JAZZ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year JAZZ has Performed in-line its overall industry.

JAZZ Sales Forecast

Next quarter’s sales forecast for JAZZ is $1.15B with a range of $1.11B to $1.20B. The previous quarter’s sales results were $1.13B. JAZZ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year JAZZ has Performed in-line its overall industry.

JAZZ Stock Forecast FAQ

What is JAZZ’s average 12-month price target, according to analysts?

Based on analyst ratings, Jazz Pharmaceuticals’s 12-month average price target is 219.54.

What is JAZZ’s upside potential, based on the analysts’ average price target?

Jazz Pharmaceuticals has 28.27% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is JAZZ a Buy, Sell or Hold?

Jazz Pharmaceuticals has a consensus rating of Strong Buy which is based on 12 buy ratings, 1 hold ratings and 0 sell ratings.

What is Jazz Pharmaceuticals’s price target?

The average price target for Jazz Pharmaceuticals is 219.54. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $263.00 ,the lowest forecast is $188.00. The average price target represents 28.27% Increase from the current price of $171.16.

What do analysts say about Jazz Pharmaceuticals?

Jazz Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of JAZZ?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Jazz Pharmaceuticals (JAZZ) Stock Forecast & Price Target

JAZZ Analyst Ratings

JAZZ Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Jazz Pharmaceuticals

JAZZ Analyst Recommendation Trends

JAZZ Financial Forecast

JAZZ Earnings Forecast

JAZZ Sales Forecast

JAZZ Stock Forecast FAQ

Detailed List of Analyst Forecasts